Capricor is a biotechnology company focused on developing and commercializing powerful cardiac stem cell treatments to regenerate the heart. Our products aim to transform the treatment of heart disease, bringing an ingenious approach to cardiac medicine and stem cell technology. Capricor is the only stem cell company creating a platform of cardiac stem cell therapies that are based on a proprietary mixture of cells from the heart itself. Capricor’s work begins and ends with the heart.

Capricor’s team of world-renowned researchers and advisory board members, including founder Dr. Eduardo Marbán, conducted ground-breaking cardiac stem cell research at Johns Hopkins University School of Medicine and the University of Rome; the results of this work has led to the revolutionary product pipeline Capricor is developing.

Today, Capricor collaborates with the Heart Institute at Cedars-Sinai Medical Center in Los Angeles through a research partnership. With clinical trials using our technology underway at Cedars-Sinai and Johns Hopkins, we are working toward speedy commercialization of our therapies. Capricor is striving to deliver our novel products into the hands of physicians to improve the lives of the many millions of people living with heart disease.